Lentiviral envelope antigenic variation and associated immune evasion are believed to
present major obstacles to effective vaccine development. Although this perception is widely …

We previously reported that an experimental live-attenuated equine infectious anemia virus (EIAV)
vaccine, containing a mutated S2 accessory gene, provided protection from disease …

… With the current assays, we cannot determine if peptide 5 contains both CTL and T-helper
epitopes or if the observed proliferation response was due to CTL expansion. As equine-…

Equine infectious anemia virus (EIAV) infection of horses provides a valuable model for
examining the natural immunological control of lentivirus infection and disease and the …

CONFERENCE PROCEEDING Proceedings of the PDA/FDA Adventitious Viruses in Biologics:
Detection and Mitigation Strategies Workshop in Bethesda, MD, USA; December 1–3, …

… For the purpose of this dissertation, only the adaptive immune responses of T-helper cells,
cytotoxic T-lymphocytes and neutralizing antibodies will be discussed. The immunology …

The biopharmaceutical industry mounted an impressive response to the rapidly evolving
COVID-19 pandemic by reprioritizing pipelines and establishing novel collaborations. While …

… Here, we show that EIAV envelope-specific T cell recognition also undergoes a shift in
epitope recognition. Initially, the T cell response is directed toward the more variable regions of …

We recently reported an attenuated EIAV vaccine study that directly examined the effect of
lentiviral envelope sequence variation on vaccine efficacy. The study [1] demonstrated for the …

Equine infectious anemia (EIA), identified in 1843 [ 1 ] as an infectious disease of horses
and as a viral infection in 1904, remains a concern in veterinary medicine today. Equine …